Rapport Therapeutics (RAPP) FY Conference Summary Company Overview - **Company**: Rapport Therapeutics (RAPP) - **Industry**: Biotechnology, specifically focusing on epilepsy and related neurological disorders Key Points and Arguments Clinical Development Progress - Rapport has made significant progress since going public a year ago, focusing on the clinical development of its lead program, RAP 219 [2][3] - Completed phase one studies, including multiple ascending dose studies and a human PET study, which have increased confidence in the pharmacology and specificity of RAP 219 [3][27] - Currently conducting a phase 2a proof of concept study in refractory focal epilepsy patients, utilizing an implantable neurostimulation device for diagnostics [3][6] Study Design and Rationale - The study design aims to produce compelling proof of concept results that are translatable to a phase three registration setting [5] - The study leverages an EEG biomarker correlated with clinical seizures, addressing the limitations of traditional clinical seizure diaries [6][9] - The trial includes an eight-week retrospective data collection period followed by a 28-day prospective period and an eight-week treatment phase [7][31] Data Expectations and Efficacy Measures - Data readout is expected in September, with a focus on achieving a 30% reduction in long episodes for 40% of participants, correlating to a 50% reduction in clinical seizures [19][22] - The study is designed to ensure a robust set of baseline characteristics, with a median clinical seizure count of 10, which positions the study favorably compared to other trials [48] Pipeline and Future Development - Rapport is also developing RAP 219 for bipolar disorder and neuropathic pain, with plans to initiate a bipolar study in Q3 [34][36] - The neuropathic pain program is currently on clinical hold due to requested protocol changes by the FDA [36][38] - A long-acting injectable formulation of RAP 219 is being explored, which could transform treatment for epilepsy patients [42][45] Financial Position - The company reported a cash position of $285 million, sufficient to fund activities through at least the end of 2026, covering the upcoming phase three trials and ongoing bipolar studies [51] Risks and Confidence - Confidence in the upcoming data readout is supported by a robust preclinical package and a high concordance rate between long episodes and electrographic seizures [47][49] - The company is optimistic about the translatability of the phase 2a results to phase three studies, with plans for an end-of-phase two meeting with the FDA following positive results [24][33] Additional Important Insights - The study design has received positive feedback from the epilepsy community, highlighting its objective analysis capabilities [9][17] - The long half-life of RAP 219 (8-14 days) is seen as beneficial for patient compliance, reducing the risk of breakthrough seizures [32] - The company aims to differentiate RAP 219 from existing treatments through its efficacy, dosing flexibility, and lack of sedation [23][27]

Summary of Rapport Therapeutics (RAPP) 2025 Conference Company Overview - **Company**: Rapport Therapeutics (RAPP) - **Industry**: Biotechnology, specifically in precision neuroscience and epilepsy treatment - **Key Personnel**: Abe Cisse (CEO), Choi Ignelzi (CFO) [1][2] Core Points and Arguments - **Vision**: Rapport aims to be a leading precision neuroscience company, focusing on receptor associated proteins to develop targeted therapies [4][5]. - **Lead Program**: RAP-two 19, an AMPA TARP gamma-eight modulator, targets specific brain areas to modulate AMPA receptors, aiming to reduce adverse effects (AEs) associated with traditional anti-seizure medications [5][6]. - **Clinical Trials**: - Currently conducting a Phase 2a proof of concept study for RAP-two 19 in focal epilepsy, fully enrolled with 30 patients, with data expected in September 2025 [7][8]. - Plans to explore RAP-two 19 in bipolar mania and peripheral neuropathic pain, with a long-acting injectable formulation also in development [8][9][10]. - **Differentiation**: RAP-two 19 is designed for once-daily dosing with a long half-life, aiming to minimize drug-drug interactions (DDIs) and improve patient adherence [12][14][15][16]. Important Data and Metrics - **Phase 1 Studies**: Completed four studies with 100 healthy volunteers, showing a favorable tolerability profile and high receptor occupancy (up to 85%) without significant sedation or motor impairment [23][24]. - **Efficacy Expectations**: The primary endpoint for the Phase 2a study is a 30% reduction in long episodes of seizures, with a target responder rate of at least 40% [38][39]. - **Safety Profile**: No serious adverse events (SAEs) reported; mild AEs observed were transient and resolved on their own [45][46]. Additional Insights - **Biomarker Utilization**: The study leverages an implantable RNS device to capture EEG activity, providing an objective measure of efficacy compared to traditional seizure diaries [28][30]. - **Regulatory Pathway**: The company plans to conduct two registrational trials for NDA submission, with the potential to start in 2026 [51][52]. - **Market Positioning**: The combination of efficacy, tolerability, and administration profile positions RAP-two 19 as a potentially best-in-class therapy for epilepsy [41][44]. Conclusion Rapport Therapeutics is advancing its lead program RAP-two 19 with a focus on precision neuroscience, aiming to address significant unmet needs in epilepsy treatment through innovative clinical trial designs and a differentiated safety profile. The upcoming data readout in September 2025 will be critical for the company's future development plans and market positioning.

Disclaimer This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identif ...

Summary of Rapport Therapeutics Investor and Analyst Day Company Overview - **Company**: Rapport Therapeutics - **Event**: Inaugural Investor and Analyst Day - **Focus**: Lead candidate RAP-two 19 for epilepsy treatment Key Points and Arguments Industry and Product Focus - **Lead Candidate**: RAP-two 19, a TARP gamma eight AMPA modulator, aimed at treating focal onset seizures in epilepsy [3][19] - **Market Size**: Focal epilepsy affects approximately 1.8 million patients in the U.S., with 30-40% being drug-resistant [32] - **Pipeline**: Fully enabled pipeline including RAP-two 19 and two late-stage discovery programs targeting chronic pain and hearing disorders [19][27] Clinical Trials and Results - **Phase Two Trial**: Ongoing trial for RAP-two 19 in focal onset seizure patients, fully enrolled with results expected in September [21][26] - **Phase One Results**: Completed four Phase I studies with 100 healthy volunteers; RAP-two 19 was safe and well-tolerated [52][53] - **Receptor Occupancy**: Achieved target receptor occupancy of 50-70% at lower doses than predicted, indicating potential for effective treatment [56][58] Scientific Insights - **Mechanism of Action**: RAP-two 19 selectively modulates AMPA receptors in specific brain regions, potentially reducing side effects associated with traditional anti-seizure medications [38][39] - **Preclinical Efficacy**: Demonstrated significant efficacy in animal models with a favorable safety profile compared to existing treatments [44][46] Management and Strategy - **Management Team**: Comprised of experienced professionals in neuroscience and drug development, emphasizing a strategic approach to building the company [15][17] - **Vision**: To create a leading precision neuroscience company, addressing the limitations of conventional small molecules in treating neurological disorders [24][25] Additional Important Content - **Unmet Needs**: Despite numerous treatment options, the number of treatment-resistant epilepsy patients remains unchanged, highlighting the need for innovative therapies [92][93] - **Patient Population**: The trial population is representative of refractory focal epilepsy patients, enhancing the translatability of results to broader populations [87] - **Long-Acting Injectable**: Potential development of a long-acting injectable formulation for RAP-two 19, which could transform treatment for epilepsy patients [29][30] Conclusion Rapport Therapeutics is positioned to address significant unmet needs in the epilepsy treatment landscape with its innovative lead candidate RAP-two 19, backed by a robust clinical and scientific foundation. The company's strategic focus on precision neuroscience and the experienced management team further enhance its potential for success in the market.

Core Viewpoint - Rapport Therapeutics is advancing its Phase 2a trial of RAP-219 in refractory focal epilepsy, which is fully enrolled and expected to report topline results in September 2025, marking a significant milestone for the company and its precision neuroscience approach [3][4][10] Group 1: Clinical Trial Updates - The Phase 2a trial of RAP-219 is designed with input from leading epilepsy experts and utilizes intracranial electroencephalography (iEEG) data to assess the drug's potential effect on long episodes (LEs), a biomarker correlated with clinical seizures (CSs) [4] - Preliminary baseline characteristics of the first 14 enrolled patients indicate that the trial population is representative of historical registrational refractory focal epilepsy trials, with a median age of 37 years and a balanced sex distribution of 7 females and 7 males [5][6] - The company anticipates providing detailed analyses of primary and secondary endpoints, treatment-emergent adverse events (TEAEs), and a consolidated safety summary from Phase 1 trials when topline results are reported [9][12] Group 2: Financial and Operational Insights - As of March 31, 2025, Rapport reported $285.4 million in cash, cash equivalents, and short-term investments, which are expected to support operations through the end of 2026 [10] - The company has conducted four Phase 1 trials involving 100 healthy volunteers, reinforcing RAP-219's differentiated tolerability profile [9][10] Group 3: Future Catalysts - Upcoming milestones include the topline readout for RAP-219 in focal epilepsy in September 2025, initiation of a Phase 2a trial in bipolar mania in Q3 2025, and updates on the diabetic peripheral neuropathic pain program in the second half of 2025 [13]

Core Insights - Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [3] - The company will participate in two upcoming investor conferences, providing opportunities for engagement with potential investors [1][2] Company Overview - Rapport Therapeutics specializes in discovering and developing small molecule precision medicines, leveraging its RAP technology platform based on pioneering discoveries related to receptor associated proteins (RAPs) in the brain [3] - The lead investigational drug, RAP-219, targets specific regions of the brain and is being pursued for the treatment of refractory focal epilepsy, bipolar mania, and diabetic peripheral neuropathic pain [3] - The company is also engaged in preclinical and late-stage discovery programs targeting chronic pain and hearing disorders [3]

Core Insights - Rapport Therapeutics, Inc. is hosting its inaugural Investor and Analyst Day on June 2, 2025, in New York City, which will also be webcast live [1][3] Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [4] - The company utilizes a unique RAP technology platform based on discoveries related to receptor associated proteins (RAPs) in the brain, aiming to create precision small molecule candidates [4] - The lead investigational drug, RAP-219, targets specific regions of the brain and is being developed for refractory focal epilepsy, bipolar mania, and diabetic peripheral neuropathic pain [4] Event Details - The Investor and Analyst Day will feature a review of the company's clinical programs, particularly the RAP-219 Phase 2a trial in refractory focal epilepsy [2] - A fireside chat with Dr. Jacqueline A. French, a prominent figure in epilepsy research, will be part of the event [2] - The event is scheduled for June 2, 2025, from 3:00 to 5:00 p.m. Eastern Time at Nasdaq MarketSite, New York City [3]

Summary of Rapport Therapeutics Conference Call Company Overview - **Company**: Rapport Therapeutics - **Focus**: Developing precision neuroscience therapeutics, particularly for focal epilepsy with lead program RAP219 [1][2] - **Background**: Company spun out from technology developed by Dr. David Brett, with a history at UCSF and Eli Lilly [3] Key Points Financials and Development Timeline - **Public Offering**: Company went public in June of the previous year [3] - **Cash Position**: Ended the year with approximately $285 million, sufficient to fund operations through at least the end of the next year [4] - **Upcoming Milestones**: - Phase two trial readout for focal onset patients expected in Q3 [4] - Initiation of bipolar mania trial in Q3 with data expected in early 2027 [4] Scientific Approach - **Technology**: Focus on receptor-associated protein technology to target specific areas in the brain, enhancing drug precision [3] - **Lead Program**: RAP219 targets AMPA receptors through the accessory protein gamma-eight TARP, aiming to reduce side effects associated with non-selective targeting [5][8] - **Preclinical and Phase One Data**: - Strong preclinical data supporting the targeting approach, with a focus on receptor occupancy and therapeutic index [14][15] - Phase one PET study confirmed receptor occupancy exceeding 80% at therapeutic concentrations [15][17] Clinical Trial Design - **Innovative Trial Design**: - Utilizes an RNS device to track long episodes of epileptic activity, providing objective data [20][25] - Aims to correlate long episode frequency with clinical seizure frequency, with a target of a 30% decrease in long episodes correlating with a 50% decrease in clinical seizures [34] - **Success Metrics**: - Aiming for a responder rate of 40% or greater in the trial participants [36] - Combination of clinical seizure diary data and objective electrographic biomarkers to validate findings [39] Market Opportunity - **Focal Epilepsy Market**: Approximately 1.8 million patients with focal epilepsy, with 40% still experiencing seizures, indicating a significant market opportunity for new treatments [49] - **Pipeline Potential**: Plans to initiate a phase two study in bipolar disorder, leveraging the mechanism of action that targets hyperactivity in the limbic system [50][51] Additional Insights - **Community Engagement**: The trial design was influenced by feedback from the medical community, emphasizing the need for more efficient and predictive drug development methods [21][30] - **Regulatory Perspective**: The FDA is seen as potentially supportive of the innovative trial design, although it remains early in the process [45] This summary encapsulates the key aspects of the conference call, highlighting the company's strategic direction, scientific innovations, and market potential.

Financial Performance - The company has not generated any revenue from product sales since its inception in February 2022, incurring significant operating losses and negative cash flows [159]. - As of March 31, 2025, the company reported net losses of $24.1 million and an accumulated deficit of $147.8 million [160]. - The net loss for the three months ended March 31, 2025, was $24.1 million, compared to a net loss of $22.7 million in 2024, indicating an increase in loss of $1.4 million [186]. - The company expects to incur significant operating losses and expenses as it advances clinical development, projecting a $2.6 million increase in workforce expenses due to headcount growth [192]. Funding and Capital - The company completed its initial public offering in June 2024, raising net proceeds of $157.6 million from the sale of 9,200,000 shares of common stock [159]. - The company has raised aggregate gross proceeds of $424.4 million from various financings as of March 31, 2025 [159]. - The company raised aggregate gross proceeds of $424.4 million from the issuance of convertible promissory notes and the sale of convertible preferred stock and common stock [193]. - The company anticipates needing to raise substantial additional capital in the future to support ongoing activities and product development [201]. - The company expects its existing cash resources to be sufficient to fund operations through at least 12 months from the issuance of the financial statements [200]. Research and Development - The company is conducting a Phase 2a proof-of-concept trial for RAP-219 in patients with refractory focal epilepsy, with topline results expected in Q3 2025 [157]. - The FDA placed a clinical hold on the IND for a Phase 2a trial of RAP-219 for diabetic peripheral neuropathic pain, requesting additional information [157]. - The company has two advanced discovery-stage nicotinic acetylcholine receptor programs targeting chronic pain and hearing disorders [158]. - Research and development expenses increased to $19.6 million for the three months ended March 31, 2025, compared to $12.5 million for the same period in 2024, representing a $7.1 million increase [186]. - The increase in research and development expenses was primarily driven by a $4.1 million rise in costs associated with the RAP-219 program, including clinical trial costs for multiple trials [187]. - The company anticipates substantial increases in research and development expenses as it advances RAP-219 through clinical development and regulatory approval [176]. Operating Expenses - Total operating expenses for the three months ended March 31, 2025, were $27.1 million, compared to $17.1 million in 2024, resulting in a $10.0 million increase [186]. - General and administrative expenses rose to $7.5 million for the three months ended March 31, 2025, up from $4.6 million in 2024, reflecting a $2.9 million increase [190]. - The company expects general and administrative expenses to continue increasing to support product candidate development and research activities [180]. Cash Flow and Investments - As of March 31, 2025, the company had cash and cash equivalents of $285.4 million, excluding restricted cash [193]. - For the three months ended March 31, 2025, the company incurred a net loss of $24.1 million, with cash used in operating activities amounting to $20.2 million [195]. - Net cash provided by investing activities for the three months ended March 31, 2025, was $21.0 million, primarily from maturities of short-term investments [197]. - During the three months ended March 31, 2024, the company had a net cash provided by financing activities of $63.7 million, primarily from the issuance of Series B convertible preferred stock [199]. Agreements and Collaborations - The company has entered into a license agreement with Janssen Pharmaceutical NV, which includes potential milestone payments totaling up to $141 million for TARPg8 products [167][168]. - The company made a non-refundable payment of $1.0 million to Janssen Pharmaceutical NV as part of a licensing agreement, with potential milestone payments totaling up to $76.0 million for development [205]. - The NeuroPace Agreement allows the company to utilize data from RNS systems in clinical trials, with an exclusivity provision preventing NeuroPace from providing similar services to competitors [170][171]. Other Financial Information - The company has recorded a full valuation allowance against its net deferred tax assets, with federal net operating loss carryforwards of approximately $13.7 million as of December 31, 2024 [185]. - The change in fair value of preferred stock tranche right liabilities was settled in March 2024, resulting in no further recognition of changes in fair value in the financial statements [183]. - Future minimum operating lease payments under non-cancelable leases total $9.3 million, with a weighted average remaining lease term of 4.4 years [203][204].

Financial Performance - Net loss for Q1 2025 was $24.1 million, compared to $22.7 million for the same period last year, reflecting an increase in operational costs [12]. - Net loss for the three months ended March 31, 2025, was $24,063,000 compared to a net loss of $22,669,000 for the same period in 2024, reflecting an increase in loss of about 6.1% [27]. - Total operating expenses rose from $17,094,000 to $27,108,000, an increase of approximately 58.8% [27]. - Net cash used in operating activities increased from $17,615,000 to $20,237,000, a rise of approximately 14.8% [29]. - Total liabilities increased from $9,506,000 to $16,217,000, an increase of approximately 70.5% [24]. - Total stockholders' equity decreased from $305,427,000 to $285,836,000, a decline of about 6.4% [24]. Research and Development - Research and Development (R&D) expenses rose to $19.6 million in Q1 2025, up from $12.5 million in the prior year, driven by clinical development costs [17]. - Research and development expenses increased significantly from $12,504,000 to $19,572,000, representing a rise of about 56.5% [27]. - Enrollment in the Phase 2a trial for RAP-219 in refractory focal epilepsy is progressing as planned, with topline results expected in Q3 2025 [4]. - The Phase 2a trial for RAP-219 in bipolar mania is set to commence in Q3 2025, with topline results anticipated in the first half of 2027 [4]. - Favorable tolerability was reported across four Phase 1 trials, with no serious adverse events and only 3% of participants discontinuing due to treatment emergent adverse events [7]. - The optimal cut point for a clinically meaningful reduction in seizure frequency was identified as a 30% reduction in long episode frequency [8]. Cash and Investments - The company ended Q1 2025 with $285.4 million in cash, cash equivalents, and short-term investments, down from $305.3 million at the end of 2024 [17]. - The company expects its cash position to fund operations through the end of 2026 [17]. - Net cash provided by investing activities was $21,031,000, contrasting with a net cash used of $41,926,000 in the previous year [29]. Corporate Events - The company plans to host its inaugural Investor and Analyst Day on June 2, 2025, featuring presentations from management and key opinion leaders [4]. Shareholder Information - The weighted-average common shares outstanding increased from 2,046,889 to 35,266,577, indicating a significant dilution of shares [27]. - General and Administrative (G&A) expenses increased to $7.5 million in Q1 2025, compared to $4.6 million in the same period last year, due to business growth and public company operational costs [17].